Zonoozi Shahrzad, Barnard Maria, Prescott Emma, Jones Romilla, Shah Farrukh T, Tzoulis Ploutarchos
Department of Diabetes, Whittington Hospital, Magdala Avenue, London, N19 5NF.
Department of Haematology, Whittington Hospital, Magdala Avenue, London, N19 5NF.
Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017004. doi: 10.4084/MJHID.2017.004. eCollection 2017.
Sitagliptin, a modern antidiabetic agent which is weight neutral and associated with low rate of hypoglycaemias, is being increasingly used in type 2 diabetes mellitus (DM). However, there is a paucity of data about its efficacy and safety in beta-thalassaemia major (β-TM). This retrospective case series of five patients (mean age of 45 years) is the first study evaluating the use of sitagliptin in patients with β-TM and DM. Four patients responded well to sitagliptin, as evidenced by a decrease in fructosamine by 77 and 96μmol/L (equivalent reduction in HbA1c of 1.5% and 1.9%) observed in two patients and reduction in the frequency of hypoglycaemia without worsening glycaemic control in two others. One patient did not respond to sitagliptin. No patients reported significant side effects. This study provides evidence that sitagliptin may be considered, with caution, for use in patients with β-TM and DM, under the close monitoring of a Diabetologist.
西他列汀是一种新型抗糖尿病药物，对体重无影响且低血糖发生率低，在2型糖尿病（DM）中的应用越来越广泛。然而，关于其在重型β地中海贫血（β-TM）患者中的疗效和安全性的数据却很少。这一回顾性病例系列研究纳入了5例患者（平均年龄45岁），是第一项评估西他列汀在β-TM合并DM患者中应用的研究。4例患者对西他列汀反应良好，其中2例患者的果糖胺分别降低了77和96μmol/L（相当于糖化血红蛋白降低1.5%和1.9%），另外2例患者低血糖发作频率降低且血糖控制未恶化。1例患者对西他列汀无反应。所有患者均未报告明显副作用。本研究提供了证据表明，在糖尿病专家的密切监测下，可谨慎考虑将西他列汀用于β-TM合并DM的患者。
